medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 3

<< Back Next >>

Med Int Mex 2022; 38 (3)

Prevalence of cutaneous lymphoma attended at the Dermatology service of a second level hospital in Mexico

Uribe-Franco RC, Puebla-Miranda M

Language: Spanish
References: 19
Page: 526-537
PDF size: 216.85 Kb.


ABSTRACT

Objective: To know the prevalence of primary cutaneous lymphoma, as well as sociodemographic data, risk factors and mortality of patients suffering it treated in the Dermatology Service of Hospital Juarez de Mexico.
Materials and Methods: An observational, descriptive, retrospective, single-center study was done comparing frequency percentages with data obtained from the clinical records of patients with primary cutaneous lymphoma treated at the Dermatology Service of Hospital Juarez de Mexico.
Results: Non-Hodgkin type lymphomas were the most frequent in our institution and of these type T was the most frequent. The three lymphomas documented in order of frequency were extranodal T NK cell lymphoma nasal type, peripheral T lymphoma, and mycosis fungoides; unlike the international literature, it affected more frequently to women.
Conclusions: Primary cutaneous lymphoma has a prevalence of 0.098%. In our hospital, it is more frequent in women, and the main type is extranodal T-cell lymphoma NK.


REFERENCES

  1. Ortonne N. Update on cutáneous lymphomas. DiagnosticHistopathology 2018; 24 (8): 301-312. https://doi.org/10.1016/j.mpdhp.2018.06.005.

  2. Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M.Primary cutaneous lymphomas: ESMO Clinical Practice Guidelinesfor diagnosis, treatment and follow-up. Ann Oncol2018; 29 (June): iv30-iv40. doi: 10.1093/annonc/mdt242.

  3. Mitteldorf C, Grabbe S, Stadler R. WHO classification andclinical spectrum of cutaneous lymphomas. Hautarzt 2017;68 (9): 682-695. doi: 10.1007/s00105-017-4025-1.

  4. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, SwerdlowSH, Jaffe ES. The 2018 update of the WHO-EORTCclassification for primary cutáneous lymphomas. Blood2019; 133 (16): 1703-1714. https://doi.org/10.1182/blood-2018-11-881268.

  5. Cannavó DA, Grees DS, Turienzo J, Merola DG, Mónica D,Milia D. Consenso-Linfoma 2018.

  6. Ghazawi FM, Alghazawi N, Le M, Netchiporouk E, GlassmanSJ, Sasseville D, Litvinov IV. Environmental and other extrinsicrisk factors contributing to the pathogenesis ofcutáneousT cell lymphoma (CTCL). Frontiers Oncol 2019; 9:1-8. doi: 10.3389/fonc.2019.00300.

  7. Navarrete LJ, Pérez CR. Linfomas cutáneos: Fisiopatologíay clasificación (primera parte). Dermatol Rev Mex 2005;49 (3): 109-122.

  8. Ron-Guerrero CS, Lucía A, Magaña R, Medina-PalaciosCL, López-Flores F. Epidemiología de los linfomas delCentro Estatal de Cancerología de Nayarit Epidemiologyof lymphomas in Nayarit, Mexico. Rev Hematol Mex 2015;16: 109-14.

  9. González KIG, Pérez DA, Bojórquez AM, González ST. Epidemiologíade linfoma cutáneo en el Servicio de Dermatooncologíadel Centro Dermatológico “Pascua”: Experiencia de20 años. Dermatol CMQ 2008; 6 (4): 221-6.

  10. Kempf W, Zimmermann AK, Mitteldorf C. Cutáneous lymphomas—An update 2019. Hematol Oncol 2019; 37 (S1):43-7. doi: 10.1002/hon.2584.

  11. Sokołowska-Wojdyło M, Olek-Hrab K, Ruckemann-Dziurdzińska K. Primary cutáneous lymphomas: Diagnosisand treatment. Postepi Dermatol Alergol 2015; 32 (5):368-83. doi: 10.5114/pdia.2015.54749.

  12. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, QuerfeldC. Primary cutáneous T-cell lymphoma (mycosis fungoidesand Sézary syndrome): Part I. Diagnosis: Clinical andhistopathologic features and new molecular and biologicmarkers. J Am Acad Dermatol 2014; 70 (2): 205.e1-205.e16. doi: 10.1016/j.jaad.2013.07.049.

  13. Yamashita T, Abbade LPF, Marques MEA, Marques SA.Mycosis fungoides and Sézary syndrome: clinical, histopathologicaland immunohistochemical review and update.An Bras Dermatol 2012; 87 (6): 817-30. doi: 10.1590/s0365-05962012000600001.

  14. Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol2007; 60 (12): 1373-7. doi: 10.1136/jcp.2007.052456.

  15. Wilcox RA. Cutaneous B-cell lymphomas: 2019 updateon diagnosis, risk stratification, and management. Am JHematol 2018; 93 (11): 1427-30. doi: 10.1002/ajh.25224.

  16. La Selva R, Violetti SA, Delfino C, Grandi V, Cicchelli S, TomasiniC, et al. A literature revision in primary cutaneousB-cell lymphoma. Indian J Dermatol 2017; 62 (2): 146-157.doi: 10.4103/ijd.IJD_74_17.

  17. Slater D. Histopathological aspects of cutáneouslymphoma. J R Soc Med 2001; 94 (7): 337-40. doi:10.1177/014107680109400705.

  18. Sauder MB, O’Malley JT, LeBoeuf NR. CD30+ lymphoproliferativedisorders of the skin. Hematol Oncol Clin NorthAm 2017; 31 (2): 317-34. doi: 10.1016/j.hoc.2016.11.006.

  19. Posada A, Valencia O, Velasquez M. Valoración de la calidadde vida en pacientes con linfoma cutáneo Dermatol RevMex 2019; 63 (1): 26-39.




2020     |     www.medigraphic.com